Overview

Effects of Atx and Oros-mph on Executive Functions

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
TC Erciyes University
Treatments:
Atomoxetine Hydrochloride
Methylphenidate
Criteria
Inclusion Criteria:

- Combined type ADHD diagnosis was made by a child psychiatrist according to DSM-IV
criteria through K-SADS interview with the patient and mother

- The Clinical Global Impression Scale (CGI-S) was applied to determine ADHD severity
and patients with a CGI-S scoreā‰„4

Exclusion Criteria:

- Psychological, neurological or psychiatric diseases other than ADHD,

- ADHD types other than combined type,

- Medication that influences cognitive processes or history of such medication,

- WISC-R scores <80 or >120